Literature DB >> 26066956

Evolving Challenges and Research-Needs Concerning Ebola.

Robert Klitzman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26066956      PMCID： PMC4504290          DOI： 10.2105/AJPH.2015.302757

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


× No keyword cloud information.
  11 in total

1.  The importance of social, cultural, and economic contexts, and empirical research in examining "undue inducement".

Authors:  Robert Klitzman
Journal:  Am J Bioeth       Date:  2005 Sep-Oct       Impact factor: 11.229

2.  Preventive misconception: its nature, presence, and ethical implications for research.

Authors:  Alan E Simon; Albert W Wu; Philip W Lavori; Jeremy Sugarman
Journal:  Am J Prev Med       Date:  2007-05       Impact factor: 5.043

Review 3.  Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies.

Authors:  Lisa A Eaton; Seth Kalichman
Journal:  Curr HIV/AIDS Rep       Date:  2007-12       Impact factor: 5.071

4.  Problems in comprehension of informed consent in rural and peri-urban Mali, West Africa.

Authors:  Michael T Krosin; Robert Klitzman; Bruce Levin; Jianfeng Cheng; Megan L Ranney
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

Review 5.  Ethical considerations of experimental interventions in the Ebola outbreak.

Authors:  Annette Rid; Ezekiel J Emanuel
Journal:  Lancet       Date:  2014-08-22       Impact factor: 79.321

6.  Evaluating novel therapies during the Ebola epidemic.

Authors:  Steven Joffe
Journal:  JAMA       Date:  2014-10-01       Impact factor: 56.272

7.  Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.

Authors:  M A Chesney; D B Chambers; J O Kahn
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-12-01

8.  Willingness to participate in HIV-1 vaccine trials among young Thai men.

Authors:  R A Jenkins; K Torugsa; L E Markowitz; C J Mason; V Jamroentana; A E Brown; S Nitayaphan
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

9.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

10.  Randomised controlled trials for Ebola: practical and ethical issues.

Authors:  Clement Adebamowo; Oumou Bah-Sow; Fred Binka; Roberto Bruzzone; Arthur Caplan; Jean-François Delfraissy; David Heymann; Peter Horby; Pontiano Kaleebu; Jean-Jacques Muyembe Tamfum; Piero Olliaro; Peter Piot; Abdul Tejan-Cole; Oyewale Tomori; Aissatou Toure; Els Torreele; John Whitehead
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321
View more
  2 in total

1.  Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.

Authors:  Christopher W Jones; Ashley L Woodford; Timothy F Platts-Mills
Journal:  BMJ Open       Date:  2020-09-17       Impact factor: 2.692

2.  Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.

Authors:  Hussein Sweiti; Obinna Ekwunife; Thomas Jaschinski; Stefan K Lhachimi
Journal:  Curr Ther Res Clin Exp       Date:  2017-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.